Prostate Cancer
AcTFirst: A phase III, open-label, multicenter, randomized study comparing AAA817 plus ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer (CAAA817B12301)
- Details
ClinicalTrials.gov ID:
NCT0685277
Diagnosis Type:
NA
USOR Number:
- Address
,
P: